Daiichi Sankyo, ArQule Halt Phase III Trial Of Cancer Drug For Failing Goal
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo and its U.S. partner ArQule are halting a Phase III trial of their ARQ197 (tivantinib) intended to treat non-small-cell lung cancer, citing an indication it would not improve survival when used in combination with erlotinib.